Doing it our way now: the approach this company pioneered is becoming the market's way
The model's full reasoning — Q4 2017 call → NOWe need answer question. Need use only transcript. Need determine if management describes company's way/approach/product being adopted/copied/moved toward by others, validating. Need YES/NO. Transcript is Pacira earnings call about EXPAREL opioid alternative. Need find if management says others are following their way, product becoming standard, being copied. They discuss partnerships, FDA guidance generic, payers recognizing, J&J collaboration, institutions adopting opioid-sparing protocols. Need be careful: The essence is market validating by imitation what company built first, while still ahead. Look for explicit descriptions of others adopting company's approach. They mention "opioid-free alternative", "opioid-sparing solutions", partners share commitment. But is that "others following the company's lead"? They have partnerships with hospitals to develop protocols. They mention "commercial payers already recognize economic advantage of reimbursing EXPAREL separately under C9290. They are supporting enhanced recovery after surgery protocols with EXPAREL and shifting many inpatient procedures to outpatient." That's adoption, not imitation? They are using company's product. But question about company's way of doing things being adopted by others in market. Could be "others are now following the company's lead" e.g., hospitals adopting opioid-sparing protocols? But management describes partners and collaborators, not necessarily competitors copying. Need identify if management explicitly states that its approach is now becoming common practice or others trying to replicate. The transcript: Dave: "The only single administration long acting local analgesic... uniquely positioned...". "In addition to our own dedicated internal initiatives, we have forged several meaningful partnerships that are helping us get the message out". Partners: J&J, Cancer Treatment Centers, etc. "These partners share our commitment to reducing the role of the operating room as gateway." Not "others following". Also FDA guidance for generic EXPAREL: "This guidance underscores tremendously high technical and financial hurdles facing any potential generic competitor... FDA guidance also highlights EXPAREL's complex multivesicular honeycomb structure... leaves us confident in long-term exclusivity in unlikely event of future generic competition." This is about barriers, not adoption.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| GGR | Gogoro Inc. | Q1 2023 | 2023-05-11 | D |
| TGT | Target Corporation | Q4 2022 | 2023-02-28 | C |
| ORAN | Orange SA | Q2 2018 | 2018-07-26 | B |
| USFD | US Foods Holding Corp. | Q1 2018 | 2018-05-12 | C |
| SHOO | Steven Madden, Ltd. | Q1 2017 | 2017-04-21 | C |
AES · Q1 2024 → YESThe question is: Does management describe that the WAY THIS COMPANY DOES THINGS is NOW BEING ADOPTED, COPIED, OR MOVED TOWARD BY OTHERS IN ITS MARKET, so that the company's own way of doing things is ...
GGR · Q1 2023 → YESThe question is: Does management describe that the way this company does things is now being adopted, copied, or moved toward by others in its market?
TGT · Q4 2022 → YESThe question is: Does management describe that the way this company does things is now being adopted, copied, or moved toward by others in its market?